Advances and challenges in malaria vaccine development

Safety and Immunogenicity of a Recombinant Nonglycosylated Erythrocyte Binding Antigen 175 Region II Malaria Vaccine in Healthy Adults Living in an Area Where Malaria Is Not Endemic

(2010) H. M. El Sahly et al.   Clinical and Vaccine Immunology

Genetically engineered, attenuated whole-cell vaccine approaches for malaria

(2010) Ashley Vaughan et al.   Human vaccines & immunotherapeutics

Adult and child malaria mortality in India: a nationally representative mortality survey

(2010) Neeraj Dhingra et al.   LANCET

Changes in the burden of malaria in sub-Saharan Africa

(2010) Wendy Prudhomme O'Meara et al.   LANCET INFECTIOUS DISEASES

Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults

(2010) Ruth D. Ellis et al.   PLoS One

A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray

(2010) P. D. Crompton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increasing incidence of malaria in the Negro River basin, Brazilian Amazon

(2010) A.C. Cabral et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Detecting signatures of balancing selection to identify targets of anti-parasite immunity

(2010) Gareth D. Weedall et al.   TRENDS IN PARASITOLOGY

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum

(2010) Blaise Genton et al.   VACCINE

The RTS,S malaria vaccine

(2010) Sofia Casares et al.   VACCINE

The Plasmodium falciparum-Specific Human Memory B Cell Compartment Expands Gradually with Repeated Malaria Infections

(2010) Greta E. Weiss et al.   PLoS Pathogens

Genetically Attenuated Parasite Vaccines Induce Contact-Dependent CD8+ T Cell Killing of Plasmodium yoelii Liver Stage-Infected Hepatocytes

(2009) A. Trimnell et al.   JOURNAL OF IMMUNOLOGY

Long‐Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children

(2009) Jahit Sacarlal et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Protection against a Malaria Challenge by Sporozoite Inoculation

(2009) Meta Roestenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’

(2009) S. L. TAKALA et al.   PARASITE IMMUNOLOGY

Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

(2009) Bernhards R. Ogutu et al.   PLoS One

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

(2009) Michele D. Spring et al.   PLoS One

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

(2009) Caterina Guinovart et al.   PLoS One

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

(2009) Mark E. Polhemus et al.   PLoS One

A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli

(2009) Debabani Roy Chowdhury et al.   PLoS One

Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children

(2009) Sodiomon B. Sirima et al.   PLoS One

Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development

(2009) S. L. Takala et al.   Science Translational Medicine

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

(2009) Issaka Sagara et al.   VACCINE

Safety and immunogenicity of GMZ2 — a MSP3–GLURP fusion protein malaria vaccine candidate

(2009) Meral Esen et al.   VACCINE

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

(2009) James F. Cummings et al.   VACCINE

Antigenic Variation in Plasmodium falciparum

(2008) Artur Scherf et al.   Annual Review of Microbiology

The conserved plant sterility gene HAP2 functions after attachment of fusogenic membranes in Chlamydomonas and Plasmodium gametes

(2008) Y. Liu et al.   GENES & DEVELOPMENT

Wheat Germ Cell-Free System-Based Production of Malaria Proteins for Discovery of Novel Vaccine Candidates

(2008) T. Tsuboi et al.   INFECTION AND IMMUNITY

Immunity to malaria: more questions than answers

(2008) Jean Langhorne et al.   NATURE IMMUNOLOGY

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

(2008) Salim Abdulla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy model for mosquito stage transmission blocking vaccines for malaria

(2008) A. SAUL   PARASITOLOGY

Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial

(2008) Fiona M. Thompson et al.   PLoS One

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02

(2008) Meta Roestenberg et al.   PLoS One

Profiling humoral immune responses to P. falciparum infection with protein microarrays

(2008) Denise L. Doolan et al.   PROTEOMICS

Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya

(2008) George W. Agak et al.   VACCINE

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

(2008) Kent E. Kester et al.   VACCINE